Evelo Biosciences, Inc. financial data

Symbol
EVLO on OTC
Industry
Pharmaceutical Preparations
Location
124 Washington Street, Suite 101, Foxboro, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2023 - Nov 9, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 67.8 % -80.4%
Debt-to-equity -241 % -129%
Return On Equity 313 %
Return On Assets -223 % -60.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 18.9M shares -82.7%
Common Stock, Shares, Outstanding 18.9M shares -82.6%
Entity Public Float 120M USD -71%
Common Stock, Value, Issued 19K USD -82.4%
Weighted Average Number of Shares Outstanding, Basic 17.4M shares +222%
Weighted Average Number of Shares Outstanding, Diluted 17.4M shares +222%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 53.5M USD -34.3%
General and Administrative Expense 20.9M USD -37.9%
Operating Income (Loss) -76.7M USD +33.2%
Nonoperating Income (Expense) -4.7M USD -11.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -81.4M USD +31.6%
Income Tax Expense (Benefit) 905K USD +87.4%
Net Income (Loss) Attributable to Parent -82.3M USD +31.2%
Earnings Per Share, Basic 8.26 USD/shares +87.5%
Earnings Per Share, Diluted 8.26 USD/shares +87.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 17.3M USD -75%
Assets, Current 18.9M USD -73.8%
Property, Plant and Equipment, Net 894K USD -83.6%
Operating Lease, Right-of-Use Asset 0 USD -100%
Other Assets, Noncurrent 797K USD -31.1%
Assets 20.6M USD -76.1%
Accounts Payable, Current 526K USD -66.1%
Accrued Liabilities, Current 4.55M USD -63.5%
Liabilities, Current 39.8M USD +47.7%
Contract with Customer, Liability, Noncurrent 7.5M USD 0%
Operating Lease, Liability, Noncurrent 0 USD -100%
Other Liabilities, Noncurrent 73K USD
Liabilities 47.3M USD -38.5%
Retained Earnings (Accumulated Deficit) -588M USD -16.3%
Stockholders' Equity Attributable to Parent -26.7M USD -386%
Liabilities and Equity 20.6M USD -76.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -20.3M USD +29.9%
Net Cash Provided by (Used in) Financing Activities -199K USD -270%
Net Cash Provided by (Used in) Investing Activities -12K USD +92.2%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 18.9M shares -82.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -20.5M USD +29.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 18.1M USD -74.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1.34M USD +38%
Deferred Tax Assets, Valuation Allowance 151M USD +28.4%
Deferred Tax Assets, Gross 151M USD +28.4%
Operating Lease, Liability 0 USD -100%
Depreciation 1.59M USD -24.3%
Payments to Acquire Property, Plant, and Equipment 12K USD -92.2%
Lessee, Operating Lease, Liability, to be Paid 8.63M USD -26.2%
Property, Plant and Equipment, Gross 2.98M USD
Operating Lease, Liability, Current 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.25M USD +3.01%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.89M USD +2.99%
Operating Lease, Weighted Average Discount Rate, Percent 0 pure -105%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.11M USD -43.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.49M USD -23.3%
Deferred Tax Assets, Operating Loss Carryforwards 65.7M USD +27.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 800K USD 0%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 11.2M USD -30.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%